SEARCH

SEARCH BY CITATION

References

  • 1
    Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815820.
  • 2
    Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202210.
  • 3
    Wali M, Harrison RF, Gow PJ, Mutimer D, Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248252.
  • 4
    Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21: 11351139.
  • 5
    Caronia S, Taylor K, Pagliaro L et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 10591063.
  • 6
    Mason AL, Lau JY, Hoang N et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328333.
  • 7
    Grimbert S, Valensi P, Levy-Marchal C et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterol Clin Biol 1996; 20: 544548.
  • 8
    Thuluvath PJ, John PR. Association between hepatitis C, diabetes mellitus, and race. A case-control study. Am J Gastroenterol 2003; 98: 438441.
  • 9
    Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592599.
  • 10
    Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Simo R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: A multivariate analysis considering the liver injury. Diabetes Care 2004; 27: 11711175.
  • 11
    Simo R, Hernandez C, Genesca J, Jardi R, Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996; 19: 9981000.
  • 12
    Krentz AJ, Dmitrewski J, Mayer D et al. Postoperative glucose metabolism in liver transplant recipients. A two-year prospective randomized study of cyclosporine versus FK506. Transplantation 1994; 57: 16661669.
  • 13
    Navasa M, Bustamante J, Marroni C et al. Diabetes mellitus after liver transplantation: Prevalence and predictive factors. J Hepatol 1996; 25: 6471.
  • 14
    Bigam DL, Pennington JJ, Carpentier A et al. Hepatitis C-related cirrhosis: A predictor of diabetes after liver transplantation. Hepatology 2000; 32: 8790.
  • 15
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825832.
  • 16
    Hourigan LF, Macdonald GA, Purdie D et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 12151219.
  • 17
    Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003; 125: 16951704.
  • 18
    Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000; 75: 355359.
  • 19
    Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696699.
  • 20
    Levy G, Villamil F, Samuel D et al. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004; 77: 16321638.
  • 21
    O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: The TMC randomised controlled trial. Lancet 2002; 360: 11191125.
  • 22
    Baid S, Cosimi AB, Farrell ML et al. Posttransplant diabetes mellitus in liver transplant recipients: Risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72: 10661072.
  • 23
    AlDosary AA, Ramji AS, Elliott TG et al. Post-liver transplantation diabetes mellitus: An association with hepatitis C. Liver Transpl 2002; 8: 356361.
  • 24
    Soule JL, Olyaei AJ, Boslaugh TA et al. Hepatitis C infection increases the risk of new-onset diabetes after transplantation in liver allograft recipients. Am J Surg 2005; 189: 552557.
  • 25
    Tueche SG. Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding. Transplant Proc 2003; 35: 14661468.
  • 26
    Proietto J, Nankervis A, Aitken P, Dudley FJ, Caruso G, Alford FP. Insulin resistance in cirrhosis: Evidence for a post-receptor defect. Clin Endocrinol (Oxf) 1984; 21: 677688.
  • 27
    Proietto J, Dudley FJ, Aitken P, Alford FP. Hyperinsulinaemia and insulin resistance of cirrhosis: The importance of insulin hypersecretion. Clin Endocrinol (Oxf) 1984; 21: 657665.
  • 28
    Taylor R, Heine RJ, Collins J, James OF, Alberti KG. Insulin action in cirrhosis. Hepatology 1985; 5: 6471.
  • 29
    Nolte W, Hartmann H, Ramadori G. Glucose metabolism and liver cirrhosis. Exp Clin Endocrinol Diabetes 1995; 103: 6374, 3029.
  • 30
    Letiexhe MR, Scheen AJ, Gerard PL et al. Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients. J Clin Endocrinol Metab 1993; 77: 12631268.
  • 31
    Cavallo-Perin P, Cassader M, Bozzo C et al. Mechanism of insulin resistance in human liver cirrhosis. Evidence of a combined receptor and postreceptor defect. J Clin Invest 1985; 75: 16591665.
  • 32
    Honeyman MC, Stone NL, Harrison LC. T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: Potential for mimicry with rotavirus and other environmental agents. Mol Med 1998; 4: 231239.
  • 33
    Narita R, Abe S, Kihara Y, Akiyama T, Tabaru A, Otsuki M. Insulin resistance and insulin secretion in chronic hepatitis C virus infection. J Hepatol 2004; 41: 132138.
  • 34
    Kim JK, Fillmore JJ, Chen Y et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 2001; 98: 75227527.
  • 35
    Svegliati-Baroni G, Ridolfi F, Di Sario A et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: Differential effects on signal transduction pathways. Hepatology 1999; 29: 17431751.
  • 36
    Sheiner PA, Schwartz ME, Mor E et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 3034.
  • 37
    Gane EJ, Naoumov NV, Qian KP et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167177.
  • 38
    Dumortier J, Bernard S, Bouffard Y, Boillot O. Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus. Liver Transpl 2006; 12: 659664.
  • 39
    Gadaleta MN, Cormio A, Pesce V, Lezza AM, Cantatore P. Aging and mitochondria. Biochimie 1998; 80: 863870.
  • 40
    Rust C, Gores GJ. Apoptosis and liver disease. Am J Med 2000; 108: 567574.
  • 41
    Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA. New onset diabetes mellitus after liver transplantation: The critical role of hepatitis C infection. Liver Transpl 2004; 10: 349355.